<DOC>
	<DOCNO>NCT01006551</DOCNO>
	<brief_summary>This open trial ziprasidone ( ZIP ) child adolescent . It design provide pilot data magnitude ZIP 's antipsychotic effect psychotic youth , dose range , acute safety , tolerability . This would inform design rigorous , randomize control trial ZIP pediatric population . The primary study hypothesis proportion pediatric subject respond treatment ziprasidone comparable great report trial ziprasidone adult .</brief_summary>
	<brief_title>Ziprasidone Early Onset Schizophrenia Spectrum Disorders</brief_title>
	<detailed_description>The study consist two phase : eight week acute phase 44 week continuation phase subject show response first eight week . All treatment open label monitor research clinician expertise treat psychotic youth . The initial titration relatively slow minimize side effect . A flexible dose strategy individual 's ultimate dose determine his/her response side effect use . The maximal dose 160mg split BID dose . We estimate average dose 120mg/d . Concurrent use benztropine , propranolol , benzodiazepine ( lorazepam clonazepam ) permit need treat emergent extrapyramidal side effect agitation . Concurrent use antidepressant mood stabilizer permit subject stable dos antidepressant mood stabilizer least four week time entry , emergence significant affective symptom maintenance phase study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Between 6 19 year old , male female . Significant psychotic symptom define behavior score least 4 ( moderate ) least one psychotic item Positive Negative Symptom Scale ( PANSS ) baseline . Subjects meet DSM IV criterion schizophrenia , schizoaffective disorder , schizophreniform disorder . Subjects free depot antipsychotic medication least six month . Good physical health . The subject give informed assent study his/her guardian able willing give inform consent . Mood stabilize treatment ( i.e. , antidepressant , lithium , carbamazepine , valproate ) permit first eight week study patient treat mood stabilizer least 30 day . Dosages remain stable first 8 week unless change discontinuation clinically indicate . A primary diagnosis substance abuse dependence . Known endocrinological neurological condition , confound diagnosis contraindication treatment antipsychotic . Subjects clear history intolerance nonresponsiveness ziprasidone . Subjects serious , short term risk suicide . Subjects pregnant refuse practice contraception study . Subjects know cardiac conduction problem especially prior QTc prolongation , know genetic risk QTc prolongation treat agent prolong QTc . These agent include antiarrhythmic agent : dofetilide ( Tkosyn ) , sotalol ( Betapace ) , quinidine ( Quinaglute ) , Class 1A III antiarrhythmic ; antipsychotic mesoridazine ( Serentil ) , thioridazine ( Mellaril ) , chlorpromazine ( Thorazine ) , droperidol ( Inapsine ) , pimozide ( Orap ) ; antiinfectives : sparfloxacin ( Zagam ) , gatifloxacin ( Tequin ) , moxifloxacin ( Avelox ) , pentamidine ( Pentam ) ; antimalarial halofantrine ( Halfan ) , mefloquine ( Lariam ) ; arsenic trioxide ( Trisenox ) , levomethadyl acetate ( Orlaam ) , dolasetron mesylate ( Anzemet ) , probucol ( Lorelcoan antilipemic ) , tacrolimus ( Prograf ) . Subjects diagnosis pervasive developmental disorder autism screen questionnaire score &gt; 15 , must clear hallucination delusion . Subjects exclude meet criterion current major depressive episode .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Schizophrenia Spectrum Disorders</keyword>
</DOC>